Index RUT
P/E -
EPS (ttm) -0.91
Insider Own 8.18%
Shs Outstand 109.36M
Perf Week -7.23%
Market Cap 7.27B
Forward P/E -
EPS next Y -1.52
Insider Trans -5.33%
Shs Float 100.41M
Perf Month 4.93%
Income -85.89M
PEG -
EPS next Q -0.28
Inst Own 69.82%
Short Float 9.48%
Perf Quarter 210.32%
Sales 0.00M
P/S -
EPS this Y -23.49%
Inst Trans -0.29%
Short Ratio 1.48
Perf Half Y 517.75%
Book/sh 3.48
P/B 19.10
EPS next Y -34.95%
ROA -31.99%
Short Interest 9.52M
Perf Year 238.61%
Cash/sh 3.31
P/C 20.08
EPS next 5Y 40.00%
ROE -34.79%
52W Range 8.28 - 99.41
Perf YTD 257.17%
Dividend Est. -
P/FCF -
EPS past 5Y -18.89%
ROI -24.59%
52W High -33.14%
Beta 1.16
Dividend TTM -
Quick Ratio 19.19
Sales past 5Y 0.00%
Gross Margin -
52W Low 702.78%
ATR (14) 5.34
Dividend Ex-Date -
Current Ratio 19.19
EPS Y/Y TTM -2.06%
Oper. Margin 0.00%
RSI (14) 45.72
Volatility 4.20% 6.77%
Employees 27
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.09
Target Price 112.26
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 3.76%
Payout -
Rel Volume 0.31
Prev Close 67.95
Sales Surprise -
EPS Surprise 1.57%
Sales Q/Q -
Earnings Apr 24 AMC
Avg Volume 6.45M
Price 66.47
SMA20 -9.68%
SMA50 7.15%
SMA200 149.16%
Trades
Volume 1,967,900
Change -2.18%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-26-24 Reiterated
Oppenheimer
Outperform
$116 → $138
Mar-07-24 Initiated
Jefferies
Buy
$110
Feb-28-24 Reiterated
Oppenheimer
Outperform
$46 → $116
May-31-23 Resumed
ROTH MKM
Buy
$32
Mar-28-23 Reiterated
Maxim Group
Buy
$15 → $25
Mar-17-23 Initiated
Stifel
Buy
$22
Jul-29-21 Resumed
BTIG Research
Buy
$20
May-25-21 Downgrade
Raymond James
Strong Buy → Outperform
$27 → $12
Jun-05-20 Initiated
BMO Capital Markets
Outperform
$14
May-05-20 Initiated
Chardan Capital Markets
Buy
$15
May-01-20 Initiated
BTIG Research
Buy
$9
Jul-16-19 Initiated
Oppenheimer
Outperform
$12
Jun-25-19 Initiated
Stifel
Buy
Mar-29-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
$10 → $21
Mar-14-19 Reiterated
Maxim Group
Buy
$28 → $20
Feb-22-19 Initiated
SVB Leerink
Mkt Perform
Dec-12-18 Initiated
B. Riley FBR
Buy
$16
Nov-19-18 Upgrade
Raymond James
Outperform → Strong Buy
Sep-18-18 Reiterated
Raymond James
Outperform
$15 → $43
Sep-18-18 Reiterated
Maxim Group
Buy
$14 → $28
Show Previous Ratings
Apr-17-24 04:05PM
Apr-13-24 08:47AM
Apr-11-24 01:49PM
12:24PM
Apr-10-24 05:45PM
08:59AM
Loading…
08:59AM
Apr-09-24 10:00AM
06:45AM
Apr-08-24 05:55AM
Apr-06-24 08:47PM
07:45AM
Apr-05-24 07:15AM
Apr-04-24 09:15AM
06:30AM
05:50AM
04:55AM
Loading…
04:55AM
Apr-02-24 05:50AM
Apr-01-24 01:49PM
Mar-31-24 10:15PM
09:31AM
06:15AM
Mar-29-24 09:15AM
09:00AM
08:51AM
Mar-28-24 01:50PM
10:52AM
(Investor's Business Daily)
05:50AM
Mar-27-24 12:42PM
12:22PM
(Investor's Business Daily)
Mar-26-24 04:15PM
(Investor's Business Daily) +16.82%
01:25PM
Loading…
01:25PM
01:02PM
12:59PM
11:58AM
11:28AM
11:17AM
11:15AM
11:13AM
10:57AM
10:07AM
08:06AM
07:12AM
07:09AM
07:03AM
05:51AM
04:11AM
Mar-25-24 06:25AM
Mar-24-24 09:15AM
Mar-23-24 05:53AM
Mar-22-24 04:55AM
Mar-21-24 08:49AM
Mar-20-24 08:30AM
08:00AM
(Investor's Business Daily)
Mar-19-24 09:45AM
Mar-17-24 09:15AM
08:50AM
Mar-16-24 08:17AM
Mar-15-24 09:45AM
05:50AM
Mar-14-24 09:38AM
Mar-13-24 07:35AM
05:03AM
Mar-11-24 06:53AM
Mar-09-24 04:47PM
Mar-08-24 01:03PM
06:47AM
Mar-07-24 12:05PM
Mar-06-24 05:50AM
Mar-05-24 11:16AM
06:15AM
Mar-04-24 04:45PM
05:58AM
Mar-03-24 09:35AM
07:41AM
Mar-01-24 05:59PM
(The Wall Street Journal) +10.60%
12:11PM
(Investor's Business Daily)
07:31AM
Feb-29-24 02:21PM
09:00AM
07:45AM
06:42AM
06:00AM
04:53AM
Feb-28-24 08:50PM
04:56PM
12:23PM
11:23AM
11:01AM
10:00AM
07:30AM
Feb-27-24 10:15PM
(Thomson Reuters StreetEvents) +121.02%
06:01PM
05:35PM
04:22PM
(The Wall Street Journal)
04:19PM
04:06PM
(Investor's Business Daily)
03:50PM
11:21AM
09:47AM
09:39AM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lian Brian President & CEO Feb 09 '24 Sale 29.90 45,000 1,345,500 2,139,882 Feb 09 08:59 PM Lian Brian President & CEO Feb 08 '24 Option Exercise 3.76 189,079 711,367 2,404,882 Feb 08 07:40 PM Rouan Sarah Kathryn Director Feb 08 '24 Option Exercise 8.32 25,000 208,000 25,000 Feb 08 07:38 PM Lian Brian President & CEO Feb 08 '24 Sale 26.87 269,079 7,230,784 2,184,882 Feb 08 07:40 PM Rouan Sarah Kathryn Director Feb 08 '24 Sale 28.05 25,000 701,250 0 Feb 08 07:38 PM Lian Brian President & CEO Jan 31 '24 Option Exercise 1.23 85,000 104,550 2,349,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 31 '24 Sale 24.71 85,000 2,100,750 2,264,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 30 '24 Option Exercise 1.23 35,000 43,050 2,299,882 Jan 30 09:05 PM Lian Brian President & CEO Jan 30 '24 Sale 23.95 35,000 838,250 2,264,882 Jan 30 09:05 PM Rouan Sarah Kathryn Director Jan 19 '24 Option Exercise 8.32 30,000 249,600 30,000 Jan 19 08:35 PM Rouan Sarah Kathryn Director Jan 19 '24 Sale 23.05 30,000 691,500 0 Jan 19 08:35 PM ZANTE GREG Chief Financial Officer Jan 04 '24 Sale 17.90 15,000 268,500 180,730 Jan 04 09:35 PM Rowland Charles A Jr Director May 16 '23 Option Exercise 1.08 40,000 43,200 70,000 May 18 06:31 PM MACARTNEY LAWSON Director May 16 '23 Option Exercise 1.19 16,000 19,040 63,965 May 18 06:30 PM Rowland Charles A Jr Director May 16 '23 Sale 25.00 40,000 1,000,000 30,000 May 18 06:31 PM MACARTNEY LAWSON Director May 16 '23 Sale 24.00 16,000 384,000 47,965 May 18 06:30 PM Lian Brian President & CEO May 01 '23 Sale 22.45 45,000 1,010,250 2,197,963 May 01 07:03 PM MACARTNEY LAWSON Director Apr 24 '23 Option Exercise 3.33 16,000 53,280 63,965 Apr 24 07:31 PM MACARTNEY LAWSON Director Apr 24 '23 Sale 22.00 16,000 352,061 47,965 Apr 24 07:31 PM Lian Brian President & CEO Apr 19 '23 Sale 21.45 35,000 750,750 2,242,963 Apr 21 07:29 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite